Quarterly report pursuant to Section 13 or 15(d)

Significant Transactions (Narrative) (Details)

v3.22.1
Significant Transactions (Narrative) (Details) - USD ($)
 3 Months Ended 9 Months Ended
Mar. 16, 2022
Nov. 01, 2021
Aug. 23, 2021
Mar. 31, 2022
Mar. 31, 2022
Mar. 31, 2021
Sep. 30, 2021
Amortization of deferred financing costs         $ 67,000 $ 0  
Purchase price allocated     $ 7,500,000        
College Station Investors LLC And Bryan Capital [Member]              
Total purchase price   $ 28,750,000          
Cash payment   28,000,000          
Fair market value of property   $ 151,450          
Percentage of base rent   6.50%          
Cash consideration for equity interest acquired   $ 50,000          
Number of warrants issued   1,289,581          
Warrants, exercise price per share   $ 1.33          
Shares issued under the Warrant   289,581          
Fair value of the warrant   $ 217,255          
College Station Investors LLC And Bryan Capital [Member] | Secured Term Loan              
Secured term loan   $ 22,375,000          
Interest rate (as percent)   3.25%          
Unrestricted cash   $ 10,000,000          
Irrevocable letter of credit   5,469,000          
Cost incurred to attain debt   $ 255,000          
Interest expense       $ 182,000 305,000    
Amortization of deferred financing costs       $ 67,000 $ 67,000    
College Station Investors LLC And Bryan Capital [Member] | IBio CMO Preferred Tracking Stock              
Warrants issuable   1          
Percentage of equity interest   0.01%          
Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, notice duration to terminate contract     30 days        
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, royalty payment term     10 years        
Collaboration and license agreement, period to cure breach of contract     60 days        
Collaboration and license agreement, notice duration to terminate contract     90 days        
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, period to cure breach of contract     30 days        
Collaboration and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]              
Milestone payments     $ 15,000,000        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, period to cure breach of contract     60 days        
Collaboration and license agreement, notice duration to terminate contract     90 days        
Collaboration and license agreement, agreement term     5 years        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Event of Non-Payment [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, period to cure breach of contract     30 days        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Financing Requirement not Met [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, notice duration to terminate contract     30 days        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | Clinical Development and Regulatory Milestone Payments [Member] | RubrYc Theraputics, Inc. [Member]              
Milestone payments     $ 15,000,000        
Collaboration, Option and License Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | No Biosimilar Product has been Approved [Member] | RubrYc Theraputics, Inc. [Member]              
Collaboration and license agreement, royalty payment term     10 years        
Series A-2 Preferred Stock [Member] | Stock Purchase Agreement [Member] | Immune-Oncology Antibodies (RTX-003) [Member] | RubrYc Theraputics, Inc. [Member]              
Stock purchase agreement, number of shares purchased 954,782   1,909,563        
Stock purchase agreement, value of shares purchased $ 2,500,000   $ 5,000,000        
Stock purchase agreement, number of shares to be purchased     954,782        
Stock purchase agreement, value of shares to be purchased     $ 2,500,000        
Preferential dividend rate percentage     8.00%        
Minimum required shares to be eligible for preferential dividend rate     1,500,000        
Proceeds from conversion of preferred stock to common stock     $ 30,000,000        
Liability for the assumed acquisition             $ 2,500,000